
Pipeline
Learn more about our R&D pipeline and ongoing trials below
Development Programs – Solid Tumor
Drug
Indication
Phase 1
Phase 2
Phase 3
BGB-24714 (SMAC Mimetic) +/- Chemotherapy
BGB-3245
(BRAF inhibitor)BGB-B167 (CEA-4-1BB bispecific antibody) +/- Tislelizumab
(anti-PD-1)Lifirafenib (RAF inhibitor) + Mirdametinib (MEK inhibitor)
(MEK inhibitor)Ociperlimab (anti-TIGIT) + Tislelizumab
Ociperlimab + Tislelizumab + BAT1706 (anti-VEGF)
Ociperlimab + Tislelizumab + Chemotherapy
Tislelizumab + Ociperlimab + Concurrent Chemoradiotherapy
Pamiparib
(PARP 1-2 inhibitor)Pamiparib + Temozolomide
Tislelizumab
Tislelizumab +/- Surzebiclimab
(anti-TIM-3) +/- LBL-007 (anti-LAG-3)Tislelizumab +/- Ociperlimab +/- LBL-007
Tislelizumab + BGB-A445
(anti-OX40)Tislelizumab + BGB-10188
(PI3K inhibitor)Tislelizumab + BGB-15025
(HPK1 inhibitor)Tislelizumab + Chemoradiotherapy
Tislelizumab + Chemotherapy/ Chemoradiotherapy
Tislelizumab + Chemotherapy
Tislelizumab + DKN-01
(anti-DKK1) + ChemotherapyTislelizumab + Fruquintinib
(VEGFR inhibitor)Tislelizumab + Lenvatinib
(VEGFR kinase inhibitor)Tislelizumab + Sitravatinib
(multikinase inhibitor)Tislelizumab + Surufatinib
(VEGFR, FGFR, CSF-1R inhibitor)Zanidatamab
(anti-HER2 bi-specific antibody)Zanidatamab + Chemotherapy+/- Tislelizumab
BC, breast cancer; BRAF, B-Raf proto-oncogene; BRCA+, breast cancer susceptibility gene-positive; BTC, biliary tract cancer; dMMR, deficient mismatch repair; ESCC, esophageal squamous cell carcinoma; ES-SCLC; extensive-stage small cell lung cancer; GBM, glioblastoma multiforme; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocelluar carcinoma; HER2-, human epidermal growth factor receptor-2–negative; HER2+, human epidermal growth factor receptor-2–positive; MSI, microsatellite instability; NSCLC, non-small cell lung cancer; OC, ovarian cancer; R/R, recurrent/refractory; SCLC, small lung cell cancer; TNBC, triple-negative breast cancer; UBC, urothelial bladder cancer.
Development Programs – Hematology
Drug
Indication
Phase 1
Phase 2
Phase 3
Tislelizumab
(anti-PD-1)BGB-10188 +- Zanubrutinib
BGB-11417 (Bcl-2 inhibitor) monotherapy
BGB-11417 + Azacitidine +/- Posaconazole
BGB-11417 + Dexamethasone +/- Carfilzomib
BGB-11417 monotherapy + zanubrutinib
BGB-16673
(BTK-targeted CDAC)Ociperlimab
(anti-TIGIT) +/- Tislelizumab or RituximabZandelisib
Zanubrutinib or Rituximab*Zanubrutinib
Zanubrutinib + Lenalidomide +/- Rituximab
Zanubrutinib + Obinutuzumab
Zanubrutinib + Rituximab
Zanubrutinib +/- Venetoclax†
* In collaboration with MEI Pharma
† This combination is being studied in the third cohort of NCT03336333
CDAC chimeric degradation activating compound; B-cell NHL, B-cell non-Hodgkins lymphoma; cHL, classical Hodgkin lymphoma; CLL, chronic lymphotic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GCB, germinal center B cell-like; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; NK, natural killer; R/R, recurrent/refractory; SLL, small lymphocytic lymphoma; WM, Waldenstrӧm macroglobulinemia.
Interactive Clinical Pipeline
Videos
PARPI Mechanism of Action
Anti-PD-1 Mechanism of Action
BTKI Mechanism of Action
Anti-TIGIT Mechanism of Action